Impact of increased patient out-of-pocket costs on oral anticoagulant discontinuation among Medicare beneficiaries with atrial fibrillation treated with apixaban
Following the formulary tier increase of apixaban from 2016 to 2017, increases in OOP costs was associated with a significantly higher probability of treatment discontinuation among Medicare beneficiaries with AF.
Authors
- Ramiro Gómez (ORCID: https://orcid.org/0000-0003-2991-1070)
- Aolin Wang (ORCID: https://orcid.org/0000-0002-3490-648X)
- Abigail Zion (ORCID: https://orcid.org/0000-0001-6598-394X)
- Elisabeth Vodicka (ORCID: https://orcid.org/0000-0002-7370-0919)
- Dominick Latrémouille-Viau (ORCID: https://orcid.org/0000-0002-8565-9220)
- Dong Cheng (ORCID: https://orcid.org/0009-0002-8689-6719)
- Grace Chen (ORCID: https://orcid.org/0000-0003-1056-6342)
- Anandkumar Dubey
- Dionne M. Hines
- Serina Deeba
Institutions
- Hudson Institute (US)
- Bristol-Myers Squibb (Germany) (DE)
- Pfizer (United States) (US)
- Bristol-Myers Squibb (United States) (US)
- Group for Research in Decision Analysis (CA)
- Analysis Group (United States) (US)
Publication Details
- Journal
- Current Medical Research and Opinion
- Published
- 2025-11-02
- DOI
- https://doi.org/10.1080/03007995.2025.2583758
- Primary Topic
- Atrial Fibrillation Management and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 0.00